| Salts and crystal forms of positive allosteric modulators of GABAA |
2022-12-14 |
2023-3-14 |
|
| Methods of use of t-type calcium channel modulators |
2022-10-25 |
2022-12-01 |
|
| Kcnt1 inhibitors and methods of use |
2022-9-20 |
2022-11-01 |
|
| Kcnt1 inhibitors and methods of use |
2022-8-25 |
2022-10-01 |
|
| Compound and method for use thereof |
2022-7-12 |
2022-9-29 |
|
| Ion channel modulators |
2022-6-23 |
2022-7-19 |
|
| FORMULATIONS OF ION CHANNEL MODULATORS AND METHODS OF PREPARATION AND USE OF … |
2022-6-23 |
2022-7-29 |
|
| Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form … |
2022-5-25 |
2022-9-15 |
|
| Methods of treatment with neuroactive steroids |
2022-4-26 |
2022-11-03 |
|
| Kcnt1 inhibitors and methods of use |
2022-4-15 |
2022-11-03 |
|
| Kcnt1 inhibitors and methods of use |
2022-4-15 |
2022-11-03 |
|
| Combinations of gaba-a receptor positive allosteric modulators and nmda … |
2022-3-30 |
2022-6-01 |
|
| Ion channel modulators |
2022-3-23 |
2022-7-14 |
|
| Ion channel modulators |
2022-3-04 |
2022-6-30 |
|
| Compounds and their methods of use |
2022-3-04 |
2022-7-14 |
|
| Formulations of t-type calcium channel modulators and methods of use thereof |
2022-1-10 |
2022-3-01 |
|
| Kcnt1 inhibitors and methods of use |
2021-12-22 |
2022-6-30 |
|
| KCNT1 INHIBITORS AND METHODS OF USE |
2021-12-03 |
2022-1-31 |
|
| KCNT1 INHIBITORS AND METHODS OF USE |
2021-12-02 |
2022-1-31 |
|
| T-type calcium channel modulators and methods of use thereof |
2021-11-09 |
2022-9-01 |
|
| Kcnt1 inhibitors and methods of use |
2021-11-02 |
2022-5-05 |
|
| Kcnt1 inhibitors and methods of use |
2021-7-06 |
2022-1-13 |
|
| Methods for the treatment of adjustment disorder |
2021-7-02 |
2022-1-06 |
|
| Methods for the treatment of depression |
2021-6-13 |
2021-7-29 |
|
| Ion channel modulators |
2021-3-31 |
2021-5-31 |
|
| Deuterated neurosteroid |
2021-2-18 |
2021-8-26 |
|
| Ion channel modulators |
2020-11-25 |
2021-6-10 |
|
| COMBINATIONS OF POSITIVE ALOSTERIC MODULATORS FOR THE GABA-A RECEPTOR AND NMDA … |
2020-10-02 |
2022-6-28 |
|
| N-piperidinyl acetamide derivatives as calcium channel blockers |
2020-8-07 |
2020-11-13 |
|
| Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and … |
2020-7-31 |
2022-8-25 |
|
| FORMULATION OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS FOR THE USE OF … |
2020-7-13 |
2021-12-15 |
|
| Substituted pyridines as ion channel modulators |
2020-5-29 |
2022-11-22 |
2022-11-22 |
| Compounds and their methods of use |
2020-5-28 |
2020-12-03 |
|
| Methods for the treatment of perimenopause and menopause |
2020-3-04 |
2022-12-21 |
|
| Compositions and methods for the treatment of KCNT1 related disorders |
2019-12-20 |
2021-7-15 |
|
| ION CHANNEL MODULATORS |
2019-5-30 |
2021-1-20 |
|
| Methods of treating epilepsy and neurodevelopmental disorders |
2018-5-16 |
2019-9-19 |
|
| Compounds and their methods of use |
2018-4-04 |
2021-11-18 |
|
| Compounds and their methods of use |
2018-2-13 |
2022-11-08 |
2022-11-08 |
| T-type calcium channel modulators and methods of use thereof |
2017-12-21 |
2021-5-06 |
|
| Fused heteroaryl compounds, and methods thereof for treating diseases, … |
2017-11-28 |
2022-3-01 |
2022-3-01 |
| Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel … |
2017-11-28 |
2023-4-18 |
2023-4-18 |
| Compounds and their methods of use |
2017-11-28 |
2021-6-24 |
|
| N-piperidinyl acetamide derivatives as calcium channel blockers |
2009-6-02 |
2021-4-30 |
|